ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Budapest, Budapest

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Budapest, Budapest, HUN:

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Active, not recruiting
Multiple Myeloma
Drug: Venetoclax
Drug: Dexamethasone

Phase 2

AbbVie
AbbVie

Budapest, Hungary and 31 other locations

low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple...

Active, not recruiting
Multiple Myeloma
Drug: Selinexor
Drug: Dexamethasone

Phase 3

Karyopharm Therapeutics
Karyopharm Therapeutics

Budapest, Hungary and 156 other locations

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Elranatamab

Phase 3

Pfizer
Pfizer

Budapest, Hungary and 209 other locations

compared with VMP alone in participants with previously untreated multiple myeloma who are ineligible for high dose chemotherapy an...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab IV
Drug: Melphalan

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Budapest, Hungary and 164 other locations

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participant...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin
Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone)

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Budapest, Hungary and 140 other locations

Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Bortezomib

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Budapest, Hungary and 135 other locations

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Mezigdomide
Drug: Dexamethasone

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Budapest, Hungary and 197 other locations

the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple...

Enrolling
Multiple Myeloma
Plasma Cell Disorder
Drug: HDP-101

Phase 1, Phase 2

Heidelberg Pharma

Budapest, Hungary and 15 other locations

subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Daratumumab SC: daratumumab + rHuPH20

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Budapest, Hungary and 163 other locations

This is a first-in-human (FIH) Phase 1/Phase 2 study for evaluating SAR445514 in monotherapy in participants with relapsed/refractory multiple...

Enrolling
Relapsed/Refractory Multiple Myeloma
Amyloid Light-chain Amyloidosis
Drug: SAR445514

Phase 1, Phase 2

Sanofi
Sanofi

Budapest, Hungary and 13 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems